Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

Authors: Eyre, Toby A ^*, Schuh, Anna, Wierda, William G, Brown, Jennifer R, Ghia, Paolo, Pagel, John M, Furman, Richard R, Cheung, Jean, Hamdy, Ahmed, Izumi, Raquel, Patel, Priti, Wang, Min Hui, Xu, Yan, Byrd, John C, Hillmen, Peter

Source: In The Lancet Haematology December 2021 8(12):e912-e921

Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.

Authors: Bibikova, Elena, Parsa, Sara, Floren, Muskan, Law, Brian, Clevenger, Tracy, Cheung, Jean, De Jesus, Gary, Burke, Kathleen, Gulrajani, Michael, Yamaguchi, Kyoko, Do, Phuong, Dougherty, Brian, Whitston, David, Brock, Graham, Munugalavadla, Veerendra, Frigault, Melanie M., Hartmann, Tanja N., Byrd, John C., Furman, Richard R., Brown, Jennifer R.

Source: Hematological Oncology; Jan2025, Vol. 43 Issue 1, p1-12, 12p

Subject Terms: BRUTON tyrosine kinase, MONONUCLEAR leukocytes, CHRONIC lymphocytic leukemia, MYC oncogenes, PROTEIN-tyrosine kinase inhibitors

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Authors: Sun, Clare ¹, Nierman, Pia ¹, Kendall, Ellen K. ¹, Cheung, Jean ⁴, Gulrajani, Michael ⁴, Herman, Sarah E.M. ¹, Pleyer, Christopher ¹, Ahn, Inhye E. ¹, Stetler-Stevenson, Maryalice ², Yuan, Constance M. ², Maric, Irina ³, Gaglione, Erika M. ¹, Harris, Hailey M. ¹, Pittaluga, Stefania ², Wang, Min Hui ⁴, Patel, Priti ⁴, Farooqui, Mohammed Z.H. ¹, Izumi, Raquel ⁴, Hamdy, Ahmed ⁴, Covey, Todd ⁴, Wiestner, Adrian ^{1, 1}

Source: In Blood 2 July 2020 136(1):93-105

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Authors: Elgamal, Sara ^*, Clevenger, Tracy ^*, Gulrajani, Michael ^*, Cheung, Jean ^*, Jeremy, Erin G. ^*, Fobare, Sydney ^*, Orwick, Shelley ^*, Sass, Ellen J. ^*, Hertlein, Erin ^*, Larkin, Karilyn T., Covey, Todd ^*, Rothbaum, Wayne P. ^*, Byrd, John C.

Source: In Blood 15 November 2022 140 Supplement 1:5936-5938

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Authors: Byrd, John C., Woszczyk, Dariusz, Illes, Arpad, Jurczak, Wojciech, Chraniuk, Dominik, Giannopoulos, Krzysztof, Mikhailova, Nataliia, Illconzai, Peter, Bhat, Seema A, Romanyuk, Nataliya, Usenko, Ganna, Kuchkova, Olha, Chandler, Jason, Bilotti, Elizabeth, Shen, Annalise, Cheung, Jean, Verstovsek, Srdan, McGreivy, Jesse, Rothbaum, Wayne, Kaźmierczak, Maciej

Source: In Blood 2 November 2023 142 Supplement 1:4634-4634

Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.

Authors: Sharma, Shringi, Pepin, Xavier, Cheung, Jean, Zheng, Lianqing, Wei, Hua, Townsley, Danielle, Han, David, Majewski, Michal, Ware, Joseph A., Mann, James, Munugalavadla, Veerendra, Sheridan, Louise, Patel, Priti, Gupta, Ashok, Tomkinson, Helen

Source: British Journal of Clinical Pharmacology; Oct2022, Vol. 88 Issue 10, p4573-4584, 12p

Subject Terms: PROTON pump inhibitors, BRUTON tyrosine kinase, NASOENTERAL tubes, THERAPEUTIC equivalency in drugs, MANTLE cell lymphoma, BIOAVAILABILITY, PROTEIN-tyrosine kinase inhibitors

Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.

Authors: Chen, Buyun, Zhou, Diansong, Wei, Hua, Yotvat, Marmor, Zhou, Li, Cheung, Jean, Sarvaria, Nicole, Lai, Richard, Sharma, Shringi, Vishwanathan, Karthick, Ware, Joseph

Source: British Journal of Clinical Pharmacology; Aug2022, Vol. 88 Issue 8, p3716-3729, 14p

Subject Terms: BRUTON tyrosine kinase, DRUG interactions, RIFAMPIN, PHARMACOKINETICS, ITRACONAZOLE, CYTOCHROME P-450 CYP3A

Rapport sur la reconnaissance par l'État des droits des victimes des essais nucléaires français et leurs impacts sur l'environnement, l'économie, le social et la santé publique en Poynésie française

Authors: Adams, Paul-Tony., Cheung, Jean Marie.

Access URL: http://hdl.handle.net/2027/mdp.39015069295023

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.

Authors: Collins, Graham P., Clevenger, Tracy N., Burke, Kathleen A., Yang, Buyue, MacDonald, Alex, Cunningham, David, Fox, Christopher P., Goy, Andre, Gribben, John, Nowakowski, Grzegorz S., Roschewski, Mark, Vose, Julie M., Vallurupalli, Anusha, Cheung, Jean, Raymond, Amelia, Nuttall, Barrett, Stetson, Dan, Dougherty, Brian A., Schalkwijk, Stein, Carnevalli, Larissa S.

Source: Leukemia & Lymphoma; Nov 2021, Vol. 62 Issue 11, p2625-2636, 12p

Subject Terms: DIFFUSE large B-cell lymphomas, CIRCULATING tumor DNA, PROTEIN-tyrosine kinases

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Authors: Bibikova, Elena ^*, Law, Brian ^*, Clevenger, Tracy ^*, Cheung, Jean ^*, De Jesus, Gary ^*, Gulrajani, Michael ^*, Yamaguchi, Kyoko ^*, Do, Phuong ^*, Burke, Kathleen ^*, Brock, Graham ^*, Munugalavadla, Veerendra, Frigault, Melanie M. ^*, Byrd, John C., Furman, Richard R., Brown, Jennifer R., Covey, Todd ^*

Source: In Blood 13 November 2019 134 Supplement 1:2571-2571

P1006: CHARACTERIZATION OF TL‐895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

Authors: Gulrajani, Michael, Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd

Source: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Authors: Alsadhan, Anfal A. ^*, Cheung, Jean ^*, Gulrajani, Michael ^*, Cook, Erika M. ^*, Pittaluga, Stefania, Davies-Hill, Theresa ^*, Izumi, Raquel, Sun, Clare C., Covey, Todd ^*, Wiestner, Adrian, Herman, Sarah E.M. ^*

Source: In Blood 29 November 2018 132 Supplement 1:4401-4401

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Authors: Covey, Todd ^*, Gulranjani, Michael ^*, Cheung, Jean ^*, Bibikova, Elena ^*, Clevenger, Tracy ^*, Krantz, Fanny ^*, Pan, Karen ^*, Yamaguchi, Kyoko ^*, De Jong, Anouk ^*, Van Lith, Bart ^*, Mittag, Diana ^*, Izumi, Raquel, Byrd, John C., Wierda, William G, O'Brien, Susan M., Furman, Richard R., Kaptein, Allard ^*

Source: In Blood 8 December 2017 130 Supplement 1:1741-1741

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF).

Authors: Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Gulrajani, Michael, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd

Source: HemaSphere; 2023 Supplement 3, Vol. 7, pe281417f-e281417f, 1p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.